source
- Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMedIncyte presented phase 1 data at the European Society for Medical Oncology congress in Madrid, highlighting its KRAS G12D inhibitor INCB161734 combined with chemotherapy for pancreatic ductal adeno…
- J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trialAt the European Society for Medical Oncology (ESMO) 2026 meeting in Madrid, Johnson & Johnson presented early clinical data from its RIPTAC platform, which the company acquired through a $3 billion…